SeaStar Medical Holding Corp (ICUCW)
US Markets · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 338K | 183K | 420K | 495K |
| Gross Profit | 311K | 169K | 408K | 449K |
| Operating Income | -1.8M | -3.6M | -3.0M | -3.6M |
| Net Income | -2.0M | -3.5M | -2.9M | -3.5M |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 135K | 1.2M |
| Gross Profit | 0.00 | 135K | 1.2M | |
| Operating Income | -11.6M | -14.2M | -17.8M | -12.2M |
| Net Income | -12.2M | -26.2M | -24.8M | -12.2M |